Magellan Rx Pharmacists Explore the Payer Perspective on Oncology Biosimilars
April 18th 2021Rebecca Borgert, PharmD, BCOP, and Jim Rebello, PharmD, from Magellan Rx Management talk about how market trends, payer formulary decisions, and international successes are shaping today's biosimilars industry.
Joseph Alvarnas, MD, Discusses Biosimilar Use at City of Hope
March 10th 2021Joseph Alvarnas, MD, a recent presenter at the Association of Community Cancer Centers annual meeting, discussed efforts to implement biosimilars at City of Hope, a clinical research center, hospital, and graduate medical school in Duarte, California.
Charles Bennett, MD, PhD, Discusses the FDA’s Biosimilar Approval Timeline
January 13th 2021Charles Bennett, MD, PhD, a hematologist and oncologist and professor in the Clinical Pharmacy and Outcomes Sciences Department of the College of Pharmacy at the University of South Carolina, discussed the FDA’s pace of biosimilar approvals and the findings from his recent study.
Part 2: Ivo Abraham, PhD, RN, Discusses the Pandemic’s Effect on Pegfilgrastim Biosimilar Use
January 5th 2021Ivo Abraham, PhD, RN, a professor with the University of Arizona Health Sciences in the Department of Pharmacy Practice and a health care consultant and co-founder of Matrix45, discussed how the pandemic is likely to impact the use of pegfilgrastim biosimilars.